产后出血临床标志物预测孕产妇死亡或严重疾病的预后准确性:世界卫生组织个体参与者数据荟萃分析
该个体参与者数据荟萃分析纳入12个数据集共312151名女性,评估产后出血临床标志物预测孕产妇死亡或严重疾病复合结局的预后准确性。在常规500 mL阈值下,测得的失血量汇总敏感性为75.7%(95%CI 60.3-86.4),特异性为81.4%(95%CI 70.7-88.8);在300 mL阈值下敏感性达83.9%(95%CI 72.8-91.1),但特异性降至54.8%(95%CI 38.0-70.5)。联合低于500 mL的失血量阈值和任何异常血流动力学征象或500 mL及以上失血量的决策规则,敏感性范围为86.9%至87.9%,特异性范围为66.6%至76.1%。
要点
- 在500 mL常规阈值下,测得失血量预测复合结局的汇总敏感性为75.7%,特异性为81.4%。
- 300 mL阈值达到首选敏感性83.9%,但特异性降至54.8%。
- 联合失血量阈值和异常血流动力学征象的决策规则敏感性为86.9%至87.9%,特异性为66.6%至76.1%。
核心结论
- 低于常规阈值的测得失血量联合异常血流动力学征象,能准确预测产后出血导致死亡或危及生命并发症的风险,并可支持更早诊断和治疗产后出血。
研究设计与样本
- 本研究为个体参与者数据荟萃分析,通过世界卫生组织全球数据征集及PubMed、MEDLINE、Embase、Cochrane图书馆和WHO试验注册库的系统检索(从数据库建库至2024年11月6日)确定合格数据集。
主要发现
- 共识别33个可能合格的数据集,成功获取并分析12个数据集,共312151名女性。
- 在500 mL常规阈值下,测得失血量预测复合结局的汇总敏感性为75.7%(95%CI 60.3-86.4),特异性为81.4%(95%CI 70.7-88.8)。
- 在300 mL阈值下达到首选敏感性83.9%(95%CI 72.8-91.1),但特异性降至54.8%(95%CI 38.0-70.5)。
- 联合低于500 mL的失血量阈值(≥300 mL至≥450 mL)和任何异常血流动力学征象(脉率>100次/分、收缩压<100 mm Hg、舒张压<60 mm Hg或休克指数>1.0)或500 mL及以上失血量的决策规则,敏感性范围为86.9%至87.9%,特异性范围为66.6%至76.1%。
关键数值与推荐
- 临床标志物和阈值选择参考WHO专家共识过程,优先最大化预后敏感性(最好>80%)而非预后特异性(最好≥50%)。
- 评估了五种临床标志物:测得失血量、脉率、收缩压、舒张压和休克指数。
- 复合结局包括孕产妇死亡或严重疾病(输血、手术干预或入住重症监护室)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postpartum haemorrhage (excessive bleeding after birth) is a leading cause of maternal mortality and morbidity worldwide. However, there is no global consensus on which clinical markers best define excessive bleeding or reliably predict adverse maternal outcomes. The aim of this study was to assess the prognostic accuracy of clinical markers of postpartum bleeding in predicting maternal mortality or severe morbidity. METHODS: In this individual participant data meta-analysis, eligible datasets were identified through a global call for data issued by WHO and systematic searches of PubMed, MEDLINE, Embase, the Cochrane Library, and WHO trial registries (from database inception to Nov 6, 2024). Studies were eligible if they included at least 200 participants with objectively measured blood loss or other clinical markers of haemodynamic instability, and reported at least one clinical outcome of interest. Individual participant data were requested for all eligible studies. For each dataset, we computed the prognostic accuracy of each clinical marker to predict a composite outcome of maternal mortality or severe morbidity (blood transfusion, surgical interventions, or admission to intensive care unit). Five clinical markers were assessed: measured blood loss, pulse rate, systolic blood pressure, diastolic blood pressure, and shock index. Results were meta-analysed through two-level mixed-effects logistic regression models, with a bivariate normal model used to generate summary accuracy estimates. Clinical marker and threshold selections were informed by a WHO expert consensus process, which placed emphasis on maximising prognostic sensitivity (preferably >80%) over prognostic specificity (preferably ≥50%). This meta-analysis was registered on PROSPERO (CRD420251034918). FINDINGS: We identified 33 potentially eligible datasets and successfully obtained and analysed full data for 12 datasets, comprising 312 151 women. At the conventional threshold of 500 mL, measured blood loss had a summary prognostic sensitivity of 75·7% (95% CI 60·3-86·4) and specificity of 81·4% (95% CI 70·7-88·8) for predicting the composite outcome. The preferred sensitivity threshold was reached at 300 mL (83·9% [95% CI 72·8-91·1]), although at the expense of reduced specificity (54·8% [95% CI 38·0-70·5]). Prognostic performance improved with a decision rule that combined the use of either blood loss thresholds less than 500 mL (≥300 mL to ≥450 mL) and any abnormal haemodynamic sign (pulse rate >100 beats per min, systolic blood pressure <100 mm Hg, diastolic blood pressure <60 mm Hg, or shock index >1·0) or 500 mL or more of blood loss, with sensitivities ranging from 86·9% to 87·9% and specificities from 66·6% to 76·1%. INTERPRETATION: Measured blood loss below the conventional threshold, combined with abnormal haemodynamic signs, accurately predicts women at risk of death or life-threatening complications from postpartum bleeding and could support earlier postpartum haemorrhage diagnosis and treatment. FUNDING: The Gates Foundation and UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction.
引用
- Gallos I, Williams CR, Price MJ, et al. Prognostic accuracy of clinical markers of postpartum bleeding in predicting maternal mortality or severe morbidity: a WHO individual participant data meta-analysis. Lancet. 2025. PMID: 41056961. doi:10.1016/S0140-6736(25)01639-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。